BioAtla to Join Jefferies Global Healthcare Conference

BioAtla, Inc., a global clinical-stage biotechnology firm listed on Nasdaq under the ticker symbol BCAB, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The event is scheduled to take place in New York, NY, from June 4 to June 6, 2024. BioAtla’s leadership will engage in a fireside chat and hold several one-on-one meetings with investors on June 5, 2024, at 8:00 a.m. ET. 

BioAtla specializes in the development of Conditionally Active Biologics (CAB) antibody therapeutics aimed at treating solid tumors. The company operates out of San Diego, California, and has a collaborative setup in Beijing, China, through its partnership with BioDuro-Sundia, which provides preclinical development services. The core technology behind BioAtla's approach involves the creation of CABs—antibodies that are designed to become active only in specific conditions, such as the unique environment of a tumor. This results in more targeted treatments that can potentially offer higher efficacy and lower toxicity compared to traditional antibodies.

BioAtla’s proprietary CAB technology enables the development of monoclonal and bispecific antibodies along with other protein therapeutic candidates. One of the key advantages of CABs is their ability to target specific cells more accurately, which can lead to more effective treatments and fewer side effects. Additionally, these therapies are designed to be more cost-efficient and predictable in their manufacturing processes. The company boasts extensive patent coverage for its CAB technology, with over 765 active patent matters, of which more than 485 are issued patents. This broad patent portfolio includes methods of making, screening, and manufacturing CAB products across various formats and compositions.

The company currently has several promising therapies in clinical development. Mecbotamab vedotin (CAB-AXL-ADC) and ozuriftamab vedotin (CAB-ROR2-ADC) are both in Phase 2 clinical trials. Mecbotamab vedotin is an antibody-drug conjugate targeting AXL, while ozuriftamab vedotin targets ROR2. Additionally, BioAtla is developing a Phase 2 stage CAB-CTLA-4 antibody named evalstotug. This novel CTLA-4 inhibitor aims to reduce systemic toxicity, potentially enabling safer combination treatments with checkpoint inhibitors like anti-PD-1 antibodies.

Furthermore, BioAtla is advancing its first dual CAB bispecific T-cell engager antibody, BA3182, currently in Phase 1 development. BA3182 targets EpCAM, a protein frequently expressed in many adenocarcinomas, while also engaging CD3-expressing T cells, aiming to stimulate a more robust immune response against tumors.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!